Hindson Benjamin R, Turner Sandra L, Millar Jeremy L, Foroudi Farshad, Gogna N Kumar, Skala Marketa, Kneebone Andrew, Christie David R H, Lehman Margot, Wiltshire Kirsty L, Tai Keen-Hun
William Buckland Radiation Oncology, Alfred Health, Melbourne, Victoria, Australia.
J Med Imaging Radiat Oncol. 2012 Feb;56(1):18-30. doi: 10.1111/j.1754-9485.2011.02336.x.
Curative radiotherapy, with or without concurrent chemotherapy, is recognized as a standard treatment option for muscle-invasive bladder cancer. It is commonly used for two distinct groups of patients: either for those medically unfit for surgery, or as part of a 'bladder preserving' management plan incorporating the possibility of salvage cystectomy. However, in both situations, the approach to radiotherapy varies widely around the world. The Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group recognised a need to develop consistent, evidence-based guidelines for patient selection and radiotherapy technique in the delivery of curative radiotherapy. Following a workshop convened in May 2009, a working party collated opinions and conducted a wide literature appraisal linking each recommendation with the best available evidence. This process was subject to ongoing re-presentation to the Faculty of Radiation Oncology Genito-Urinary Group members prior to final endorsement. These Guidelines include patient selection, radiation target delineation, dose and fractionation schedules, normal tissue constraints and investigational techniques. Particular emphasis is given to the rationale for the target volumes described. These Guidelines provide a consensus-based framework for the delivery of curative radiotherapy for muscle-invasive bladder cancer. Widespread input from radiation oncologists treating bladder cancer ensures that these techniques are feasible in practice. We recommend these Guidelines be adopted widely in order to encourage a uniformly high standard of radiotherapy in this setting, and to allow for better comparison of outcomes.
根治性放疗,无论是否联合同期化疗,均被视为肌层浸润性膀胱癌的标准治疗选择。它通常用于两类不同的患者群体:一类是那些因身体状况不适合手术的患者,另一类是作为“保膀胱”管理计划的一部分,该计划包含挽救性膀胱切除术的可能性。然而,在这两种情况下,世界各地的放疗方法差异很大。澳大利亚和新西兰放射肿瘤学泌尿生殖组认识到需要制定关于根治性放疗中患者选择和放疗技术的一致的、基于证据的指南。在2009年5月召开的一次研讨会之后,一个工作小组整理了意见,并进行了广泛的文献评估,将每项建议与现有最佳证据联系起来。在最终批准之前,这一过程不断向放射肿瘤学泌尿生殖组的成员重新展示。这些指南包括患者选择、放射靶区勾画、剂量和分割方案、正常组织限制和研究技术。特别强调了所描述靶区体积的理论依据。这些指南为肌层浸润性膀胱癌的根治性放疗提供了一个基于共识的框架。治疗膀胱癌的放射肿瘤学家的广泛参与确保了这些技术在实践中是可行的。我们建议广泛采用这些指南,以鼓励在这种情况下实现统一的高标准放疗,并便于更好地比较治疗结果。